Você procurou por: ulipristal (Inglês - Esloveno)

ulipristal acetate
ulipristal acetat

esmya ulipristal acetate
esmya ulipristalacetat

ellaone 30 mg tablet ulipristal acetate
ellaone 30 mg tableta ulipristalacetat

the active substance is ulipristal acetate.
učinkovina je ulipristalacetat.

each tablet contains 30 mg ulipristal acetate
ena tableta vsebuje 30 mg ulipristalacetata.

ulipristal acetate is excreted in human milk.
ulipristalacetat se izloča v mleko pri človeku.

each tablet contains 5 mg of ulipristal acetate.
ena tableta vsebuje 5 mg ulipristalacetata.

esmya contains the active substance ulipristal acetate.
zdravilo esmya vsebuje zdravilno učinkovino ulipristalacetat.

ulipristal acetate exerts a direct effect on the endometrium.
ulipristalacetat ima neposreden učinek na endometrij.

potential for other medicinal products to affect ulipristal acetate
možnost vpliva drugih zdravil na ulipristalacetat

ulipristal acetate should only be prescribed after careful diagnosis.
ulipristalacetat se sme predpisati samo po skrbni diagnozi.

ulipristal acetate has a specific pharmacodynamic action on the endometrium:
ulipristalacetat ima specifično farmakodinamično delovanje na endometrij.

ellaone is a medicine that contains the active substance ulipristal acetate.
ellaone je zdravilo, ki vsebuje zdravilno učinkovino ulipristalacetat.

ulipristal acetate does not affect serum levels of tsh, acth or prolactin.
ulipristalacetat ne vpliva na ravni tsh, acth ali prolaktina v serumu.

the effects of ulipristal acetate on bcrp are unlikely to have any clinical consequences.
ni verjetno, da bi imeli učinki ulipristalacetata na bcrp kakršne koli klinične posledice.

renal impairment is not expected to significantly alter the elimination of ulipristal acetate.
ni pričakovati, da bi ledvična okvara bistveno spremenila izločanje ulipristalacetata.

odds ratio [95% ci] of pregnancy risk, ulipristal acetate vs levonorgestrel2
kvocient tveganja [95% ci] za nosečnosti, ulipristalacetat versus levonorgestrel2

carcinogenicity studies (in rats and mice) showed that ulipristal acetate is not carcinogenic.
Študije kancerogenosti (na podganah in miših) so pokazale, da ulipristalacetat ni kancerogen.

no pharmacokinetic studies with ulipristal acetate have been performed in females with impaired renal or hepatic function.
farmakokinetičnih študij z ulipristalacetatom pri ženskah z oslabljeno ledvično ali jetrno funkcijo niso izvedli.

medicinal products containing progestagen should not be taken within 12 days after cessation of ulipristal acetate treatment.
zdravil, ki vsebujejo progestagen, bolnice ne smejo jemati 12 dni po prenehanju zdravljenja z ulipristalacetatom.